Replies to post #149568 on Biotech Values

[vinmantoo]

Not much movement in ONXX today. I assume this is because Regorfenib approval was expected, and the boost to ONXX bottom-line isn't going to be great considering the market size and the 20% share ONXX gets. Perhaps adding approval for GIST will provide a bit more of a jump. However, the big news people are likely waiting for is how sales of Carfilzomib start out.

[p3analyze]

JQ, does ONXX have much to gain from co-promotion in the US, e.g. higher profit sharing compared to global ex-US royalty rate? TIA

[DewDiligence]

Bayer/ONXX—FDA grants priority review for Stivarga in GIST:

http://finance.yahoo.com/news/bayers-stivarga-regorafenib-tablets-drug-150300408.html

Stivarga was FDA-approved for metastatic CRC a few weeks ago (#msg-79989122).